ONK Therapeutics News:

Press Release 10th Dec. 2018

ONK Therapeutics announced as one of the 27 ground breaking projects to receive funding Under Disruptive Technologies Innovation Fund

Today, The Department for Business, Enterprise and Innovation through the Disruptive Technologies Innovation Fund announced that Galway based ONK Therapeutics Ltd, together with it’s consortium partners Janssen Sciences Ireland UC based in Cork and the Centre for Cell Manufacturing Ireland based at NUI Galway, are one of it’s 27 chosen projects to receive funding in order to further develop it’s research into the treatment of cancer, the second biggest killer of humans globally.
ONK Therapeutics is an NK cell therapy company focused on cancer treatment.  NK cells are one of the body’s strongest defences against cancer, being one of the most tumour cytotoxic components of the human immune system. ONK Therapeutics’s strategy is to develop novel, off the shelf, NK cell-based therapies for cancer. Further, the company is seeking to enhance these NK cells through the introduction of a series of genetic modifications, creating a technology platform that can be tailored to multiple cancers.
Following this morning’s announcement by An Taoiseach, Leo Varadkar TD and Minister for Business, Enterprise and Innovation, Heather Humphreys, Professor Michael O’Dwyer, Chief Scientific Officer of ONK Therapeutics welcomed the announcement and said that he looked forward to developing novel NK cell based therapeutics for cancer in collaboration with consortium partners, NUI Galway and Janssen.

For further information please contact:
Prof. Michael O’Dwyer
Founder & Director of ONK Therapeutics
Email: michael.odwyer@onktherapeutics.ie
Tel: +353 87 250 6638

We will be presenting two abstracts at the upcoming Annual Meeting of the American Society of Hematology (http://www.hematology.org).
For more information please see,

Industry News:

10th December 2018
An Taoiseach and Minister Humphreys announce over €75m for 27 groundbreaking projects under Disruptive Technologies Innovation Fund

  • Collaborative projects include household electricity generation, sepsis treatments, coastal flooding supports & medical 3D printing
  • Project Ireland 2040 fund allocating €500m over next 10 years
  • Key element of Government’s ‘Future Jobs’ initiative

An Taoiseach, Leo Varadkar TD, Minister for Business, Enterprise and Innovation, Heather Humphreys TD have unveiled the 27 innovative projects who are sharing over €75 million in funding out to 2021 under the first tranche of the Disruptive Technologies Innovation Fund.
Full text is article is available here

RSS Biotech News

  • PwC report sees pharma-biotech deals 'to be extremely active in 2020' January 24, 2020
    A report out this week by PwC thinks that biotech could be in for a good year for deals as it sees the momentum from 2019 growing, although don’t expect many megadeals.
  • Drug 'chaperone' fends off Alzheimer's in mice by preventing toxic protein clumping January 24, 2020
    Researchers at Temple University say they’ve developed a drug that prevents the buildup of the proteins amyloid beta and tau in the brain, a hallmark of Alzheimer's disease. The drug restores a molecule inside brain cells that separates out the toxic proteins, and it proved promising in mouse models of Alzheimer's that had not yet […]
  • Gilead mulls repositioning failed Ebola drug in China virus  January 24, 2020
    Gilead is considering repositioning NUC inhibitor remdesivir as a treatment for the coronavirus now sweeping across parts of China. The antiviral last made headlines when Gilead tested it, with little success, as a treatment for Ebola virus.
  • Ipsen's $1B bet on the ropes after interim phase 3 analysis January 24, 2020
    Ipsen has paused a phase 3 trial of palovarotene after an interim analysis found it is unlikely to meet its primary efficacy endpoint. The setback is another blow for the retinoic acid receptor gamma agonist, which has run into safety and efficacy problems since Ipsen acquired it in a $1.3 billion (€1.1 billion) takeover of […]
  • Repurposing non-oncology drugs to treat cancer January 24, 2020
    Scientists at the Broad Institute and the Dana-Farber Cancer Institute screened thousands of existing drug compounds and unexpectedly found 49 they believe could be repurposed for treating cancer. They also identified novel targets that could aid in the development of new cancer drugs.
  • ATAI, DemeRx pursue 'neurochemical reset' for addiction in $22M JV January 24, 2020
    ATAI Life Sciences and DemeRx are setting up a joint venture to develop a one-and-done treatment for opioid use disorder that works by giving people a “neurochemical reset.” Ibogaine has previously been sold as a stimulant and antidepressant in France and has been studied in other countries as a treatment for addiction.
  • Chutes & Ladders—Lonza seeking experience in CEO successor January 23, 2020
    Lonza looking for replacement for former CEO Funk; Hengrui's longtime chairman Piaoyang set to step aside; Vyaire taps Agarwal as CEO.
  • Deloitte, Rady Children's to launch medical drone delivery program to beat San Diego traffic January 23, 2020
    No one likes to be stuck in traffic—but delays can be particularly stressful when you’re transporting laboratory samples needed to diagnose sick children and infants.
  • In conversation with Myrtle Potter, CEO of Sumitovant January 23, 2020
    Sumitovant CEO Myrtle Potter discusses the $3 billion deal between Roivant and Sumitomo Dainippon that set up Sumitovant, a new umbrella containing five Vants now owned by the Japanese Pharma, as well as her role at Sumitovant and what's up in 2020.
  • FDA approves Medtronic's tiny, wireless, minimally invasive pacemaker implant January 23, 2020
    The FDA approved a new, tiny pacemaker from Medtronic that does not require the wiring of separate electrodes between the implant and the heart. Less than one-tenth the size of traditional pacemakers and described as one of the world’s smallest, the Micra AV device is designed to be placed entirely within the heart’s right ventricle.

RSS Pharma News